Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2008 Jul 16;2008(3):CD000193.
doi: 10.1002/14651858.CD000193.pub3.

Somatostatin analogues for acute bleeding oesophageal varices

Peter C Gøtzsche  1 , Asbjørn Hróbjartsson
Affiliations
Meta-Analysis

Somatostatin analogues for acute bleeding oesophageal varices

Peter C Gøtzsche et al. Cochrane Database Syst Rev. .

Abstract

Background: Somatostatin and its derivatives are sometimes used for emergency treatment of bleeding oesophageal varices in patients with cirrhosis of the liver.

Objectives: To study whether somatostatin or its analogues improve survival or reduce the need for blood transfusions in patients with bleeding oesophageal varices.

Search strategy: PubMed and The Cochrane Library were searched (November 2007). Reference lists of publications, contacts with authors.

Selection criteria: All randomised trials comparing somatostatin or analogues with placebo or no treatment in patients suspected of acute or recent bleeding from oesophageal varices.

Data collection and analysis: The outcome measures extracted were: mortality, blood transfusions, use of balloon tamponade, initial haemostasis and rebleeding. Intention-to-treat analyses including all randomised patients were conducted if possible; a random-effects analysis was preferred if there was significant heterogeneity between the trials (P < 0.10). The trials were divided in two groups: trials with a low risk of bias, which had concealed allocation of patients and were double-blind, and other trials.

Main results: We included 21 trials (2588 patients). The drugs did not reduce mortality significantly (relative risk 0.97, 95% confidence interval (CI) 0.75 to 1.25, for the trials with a low risk of bias, and 0.80, 95% CI 0.63 to 1.01, for the other trials). Units of blood transfused were 0.7 (0.2 to 1.1) less with drugs in the trials with a low risk of bias and 1.5 (0.9 to 2.0) less in the other trials. Number of patients failing initial haemostasis was reduced, relative risk 0.68 (0.54 to 0.87). Number of patients with rebleeding was not significantly reduced for the trials with a low risk of bias, relative risk 0.84 (0.52 to 1.37) while it was substantially reduced in the other trials, relative risk 0.36 (0.19 to 0.68). Use of balloon tamponade was rarely reported.

Authors' conclusions: The need for blood transfusions corresponded to one half unit of blood saved per patient. It is doubtful whether this effect is worthwhile. The findings do not suggest a need for further placebo-controlled trials of the type reviewed here. A large placebo controlled trial enrolling thousands of patients is needed if one wishes to rule out the possibility that a worthwhile effect on mortality might have been overlooked.

PubMed Disclaimer

Conflict of interest statement

Peter Gøtzsche was the lead investigator of one of the included trials. Somatostatin was purchased at usual market price and the pharmaceutical company delivering coded drugs did not provide financial support to the trial and was not involved in its planning, execution, analysis, or publication.

Figures

1.1
1.1. Analysis
Comparison 1 Somatostatin analogues versus placebo or no treatment, Outcome 1 Mortality.
1.2
1.2. Analysis
Comparison 1 Somatostatin analogues versus placebo or no treatment, Outcome 2 Number of transfusions.
1.3
1.3. Analysis
Comparison 1 Somatostatin analogues versus placebo or no treatment, Outcome 3 Number with balloon tamponade.
1.4
1.4. Analysis
Comparison 1 Somatostatin analogues versus placebo or no treatment, Outcome 4 Number failing initial haemostasis.
1.5
1.5. Analysis
Comparison 1 Somatostatin analogues versus placebo or no treatment, Outcome 5 Number with rebleeding.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Avgerinos 1997 {published data only}
    1. Avgerinos A, Nevens F, Raptis S, Fevery J, and the ABOVE Study Group. Early administration of natural somatostatin (S) increases the efficacy of sclerotherapy (ES) in Acute Bleeding Oesophageal Variceal Episodes: the European ABOVE Study [abstract]. Gut 1996;39:A1.
    1. Avgerinos A, Nevens F, Raptis S, Fevery J, and the ABOVE Study Group. Early administration of natural somatostatin (S) increases the efficacy of sclerotherapy (ES) in acute bleeding oesophageal variceal episodes: The European ABOVE Study [AASLD abstract]. Hepatology 1996;24(4 Pt 2):191A.
    1. Avgerinos A, Nevens F, Raptis S, Fevery J, and the ABOVE Study Group. Early administration of natural somatostatin (S) increases the efficacy of sclerotherapy (ES) in acute bleeding oesophageal variceal episodes: the European ABOVE Study [UEGW abstract]. United European Gastroenterology Week, Paris 1996;OP1:0001.
    1. Avgerinos A, Nevens F, Raptis S, Fevery J, and the ABOVE Study Group. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 1997;350:1495‐9. [MEDLINE: ] - PubMed
    1. Avgerinos A, Nevens F, Raptis S, Fevery J, for the ABOVE study group. Somatostatin for acute oesophageal variceal bleeding [reply]. Lancet 1998;351:911‐2. - PubMed
Besson 1995 {published and unpublished data}
    1. Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. New England Journal of Medicine 1995;333:555‐60. [MEDLINE: ] - PubMed
    1. Ingrand P, Rodriguez B, Silvain C, Beauchant M, and a multicenter group. Predictive factors of early variceal bleeding control after emergency sclerotherapy: role of octreotide [abstract]. Journal of Hepatology 1997;26 Suppl 1:P/C02‐15.
    1. Silvain C, Multricentric Group. A comparison of octreotide combined with endoscopic sclerosis to endoscopic sclerosis alone in the treatment of acute variceal bleeding: a randomized double‐blind placebo‐controlled trial [EASL abstract]. Journal of Hepatology 1995;23 Suppl 1:S70.
Burroughs 1990 {published data only}
    1. Burroughs AK, McCormick PA, Hughes MD, Sprengers D, D'Heygere F, McIntyre N. Randomized, double‐blind, placebo‐controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early rebleeding. Gastroenterology 1990;99:1388‐95. [MEDLINE: ] - PubMed
    1. Burroughs AK, McCormick PA, Sprengers D, Hughes M, D'Heygere F, McIntyre N. Randomised double‐blind placebo controlled study of somatostatin for control of variceal bleeding [abstract]. Gut 1988;29(10):A1495. - PubMed
    1. Burroughs AK, McCormick PA, Sprengers D, Hughes M, D'Heygere F, McIntyre N, et al. Randomized, double‐blind placebo controlled study of somatostatin for control of variceal bleeding [AASLD abstract]. Hepatology 1988;8:1221. - PubMed
Burroughs 1996 {published data only}
    1. Burroughs AK. International Octreotide Varices Study Group. Double blind RCT of 5 day octreotide versus placebo, associated with sclerotherapy for trial/failures [AASLD abstract]. Hepatology 1996;24:352A.
Calès 2001 {published data only}
    1. Calès P for the French Club for the Study of Pht. Early administration of vapreotide, a new somatostatin analogue, and endoscopic therapy for acute portal hypertensive bleeding in patients with cirrhosis. A randomized trial [abstract 1035]. Hepatology 1999;30(4):419A.
    1. Calès P, Masliah C, Bernard B, Garnier P‐P, Silvain C, Szostak‐Talbodec N, et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. French Club for the Study of Portal Hypertension. New England Journal of Medicine 2001;344(1):23‐8. - PubMed
Farooqi 2000 {published data only}
    1. Farooqi JI, Farooqi RJ, Haq N, Siddiq‐Ur‐Rehman, Mahmood S. Treatment and outcome of variceal bleeding ‐ a comparison of two methods. Journal of the College of Physicians and Surgeons in Pakistan 2000;10:131‐3.
Freitas 2000 {published data only}
    1. Freitas DS, Sofia C, Pontes JM, Gregorio C, Cabral JP, Andrade P, et al. Octreotide in acute bleeding esophageal varices: a prospective randomized study. Hepatogastroenterology 2000;47(35):1310‐4. - PubMed
Gøtzsche 1995 {published and unpublished data}
    1. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Somatostatin versus placebo in bleeding oesophageal varices: randomised trial and meta‐analysis. BMJ (Clinical Research Ed.) 1995;310:1495‐8. [MEDLINE: ] - PMC - PubMed
Isaac 1994 {published data only}
    1. Isaac J. Pre‐sclerotherapy treatment with somatostatin in bleeding oesophageal varices [abstract]. Journal of Gastroenterology and Hepatology 1994;9(3):A35.
Morales 2007 {published data only}
    1. Morales GF, Pereira Lima JC, Hornos AP, Marques DL, Costa CS, Lima Pereira L, et al. Octreotide for esophageal variceal bleeding treated with endoscopic sclerotherapy: a randomized, placebo‐controlled trial. Hepatogastroenterology 2007;54(73):195‐200. - PubMed
Moretó 1994 {published and unpublished data}
    1. Moretó M, Zaballa M, Ruiz‐Rebollo L, Calderón A, Ibánez S, Ojembarrena E, et al. Somatostatin as an adjuvant to emergency sclerotherapy of bleeding esophageal varices [abstract]. Endoscopy 1994;26:407.
    1. Moretó M, Zaballa M, Ruiz‐Rebollo L, Calderón A, Ibánez S, Ojembarrena E, et al. Somatostatin as an adjuvant to emergency sclerotherapy of bleeding esophageal varices [abstract]. Gut 1994;35:A178.
Pauwels 1994 {published data only}
    1. Pauwels A, Florent C, Desaint B, Guivarch P, Van H, Levy V‐G. Terlipressine et somatostatine dans le traitement des hémorragies par rupture de varices oesophagiennes [letter]. Gastroenterology and Clinical Biology 1994;18:388‐9. [MEDLINE: ] - PubMed
Shah 1996 {published data only}
    1. Shah HA, Mumtaz K, Jafri W, Abid S, Hamid S, Ahmad A, et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the management of gastro‐oesophageal variceal hemorrhage. Journal of Ayub Medical College, Abbottabad 2005;17(1):10‐4. - PubMed
    1. Shah SHA, Jafri SMW, Ahmed A, Hamid SS, Khan AH. Octreotide use in acute variceal haemorrhage: a prospective randomized study [United European Gastroenterology Week abstract 1215]. Endoscopy 1996;28:S51.
Shiha 1996 {published and unpublished data}
    1. Shiha G, Hamid M, El‐Said SS, Farag FM, Azzam F, Askalany H. Octreotide infusion plus emergency sclerotherapy versus sclerotherapy alone for the control of bleeding oesophageal varices: a prospective randomized clinical trial. Mansoura Medical Journal 1996;26:109‐21.
    1. Shiha G, Sayed S, Hamid M, Farag M, Azzam F, Assalany H. Octreotide infusion plus emergency sclerotherapy versus sclerotherapy alone for the control of bleeding oesophageal varices: a prospective randomized clinical trial [UEGW abstract]. Excerpta Medica. 5th United European Gastroenterology Week, Paris 2‐6 Nov. 1996:OT51‐1066.
Signorelli 1996 {published data only}
    1. Signorelli S, Negrini F, Paris B, Bonelli M, Girola M. Sclerotherapy with or without somatostatin or octreotide in the treatment of acute variceal haemorrhage: our experience [abstract]. Gastroenterology 1996;110:A1326.
Signorelli 1997 {published data only}
    1. Signorelli S, Paris B, Negrini F, Bonelli M, Auriemma L. Esophageal varices bleeding: comparison between treatment with sclerotherapy alone vs sclerotherapy plus octreotide [abstract]. Hepatology 1997;26(4 Pt 2):137A.
Souza 2003 {published data only}
    1. Souza FC, Arantes V, Cambraia RD, Cangussu LOF, Couto OFM, Teixeira R. Randomized, double blind, trial of octreotide plus endoscopic treatment in controlling gastroesophageal variceal bleeding [abstract]. Journal of Hepatology 2003;38:70.
Sung 1995 {published and unpublished data}
    1. Sung JJY, Chung SCS, Yung MY, Lai CW, Lau JYW, Lee YT, et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995;346:1666‐9. [MEDLINE: ] - PubMed
Valenzuela 1989 {published data only}
    1. Valenzuela JE, Schubert T, Fogel MR, Strong RM, Levine J, Mills PR, et al. A multicenter, randomized, double‐blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology 1989;10(6):958‐61. [MEDLINE: ] - PubMed
Villanueva 2001 {published data only}
    1. Villanueva C, Ortiz J, Minana J, Soriano G, Sabat M, Boadas J, et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001;121:110‐7. - PubMed
Zuberi 2000 {published data only}
    1. Zuberi BF, Baloch Q. Comparison of endoscopic variceal sclerotherapy alone and in combination with octreotide in controlling acute variceal hemorrhage and early rebleeding in patients with low‐risk cirrhosis. American Journal of Gastroenterology 2000;95(3):768‐71. - PubMed
    1. Zuberi BF, Balouch Q. Endoscopic variceal sclerotherapy and octreotide in management of variceal haemorrhage and early re‐bleeding [abstract]. Journal of Gastroenterology and Hepatology 1999;14:A15.

References to studies excluded from this review

Brunati 1996 {published data only}
    1. Brunati S, Ceriani R, Curioni R, Brunelli L, Repaci G, Morini L. Sclerotherapy alone vs. sclerotherapy plus terlipressin vs. sclerotherapy plus octreotide in the treatment of acute variceal haemorrhage [abstract]. Hepatology 1996;24(4 Pt 2):207A.
    1. Ceriani R, Curioni R, Morini L, Repaci G, Brunati S. Sclerotherapy alone (ES) vs. sclerotherapy plus terlipressin (EST) vs. sclerotherapy plus octreotide (ESO) in the treatment of acute variceal bleeding [abstract]. Gastroenterology 1997;112:A1238.
D'Amico 1998 {published data only}
    1. D'Amico G, Politi F, Morabito A, D'Antoni A, Guerrera D, Giannuoli G, et al. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial. Hepatology 1998;28:1206‐14. - PubMed
Jenkins 1997 {published data only}
    1. Jenkins SA, Baxter JN, Critchley M, Kingsnorth AN, Makin CA, Ellenbogen S, et al. Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. BMJ (Clinical Research Ed.) 1997;315:1338‐41. [MEDLINE: ] - PMC - PubMed
Primignani 1995 {published data only}
    1. Primignani M, Andreoni B, Carpinelli L, Capria A, Rocchi G, Lorenzini I, et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: a randomized, double‐blind, placebo‐controlled, multicenter trial. Hepatology 1995;21(5):1322‐7. [MEDLINE: ] - PubMed
Ruiz del Arbol 1994 {published data only}
    1. Ruiz del Arbol L, Monescillo A, Arocena C, Defarges V, Gisbert J, Vicente M, et al. The pharmacological therapy during the treatment of acute variceal bleeding (A.V.B.) evaluated by variceal pressure measurement [IASL abstract]. Hepatology 1994;19(4):119I.
Shields 1993 {published data only}
    1. Shields R, Jenkins SA, Baxter JN, Sutton R, Ellenbogen S. Octreotide in the long term management of portal hypertension: preliminary results of a prospective randomised controlled clinical trial [abstract]. Gastroenterology Supplements. 1993; Vol. 4:A991.
Silva 2004 {published data only}
    1. Silva G, Quera R, Fluxa F, Sanhueza E, Segovia R, Brahm J, et al. [Octreotide administration and/or endoscopic treatment in cirrhotic patients with acute variceal bleeding: a multicentric study]. Revista Medica de Chile 2004;132(3):285‐94. - PubMed
UCB trial 1996 {published data only (unpublished sought but not used)}
    1. Somatostatin in the control of early rebleeding after sclerotherapy for acute bleeding varices: a multicentre, double‐blind randomised placebo‐controlled study. Trial MPCE93M0601/1V, sponsored by UCB, Belgium. Unpublished.

Additional references

Albillos 1994
    1. Albillos A, Rossi I, Iborra J, Lledo JL, Calleja JL, Barrios C, et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. Journal of Hepatology 1994;21(1):88‐94. [MEDLINE: ] - PubMed
Baveno II 1996
    1. Franchis R, editor. Portal hypertension II. Proceedings of the second Baveno international consensus workshop on definitions, methodology and therapeutic strategies. Oxford, UK: Blackwell Science Ltd, 1996.
Bornman 1994
    1. Bornman PC, Krige JEJ, Terblanche J. Management of oesophageal varices. Lancet 1994;343(8905):1079‐84. [MEDLINE: ] - PubMed
Chalmers 1990
    1. Chalmers I. Underreporting research is scientific misconduct. JAMA 1990;263:1405‐8. - PubMed
Chan 2004
    1. Chan A‐W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457‐65. - PubMed
Cirera 1995
    1. Cirera I, Feu F, Luca A, Garcia‐Pagan JC, Fernandez M, Escorsell A, et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double‐blind hemodynamic investigation. Hepatology 1995;22(1):106‐11. [MEDLINE: ] - PubMed
D'Amico 2003
    1. D'Amico G, Pietrosi G, Tarantino I, Pagliaro L. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta‐analysis. Gastroenterology 2003;124:1277‐91. - PubMed
Escorsell 2001
    1. Escorsell A, Bandi JC, Andreu V, Moitinho E, Garcia‐Pagan JC, Bosch J, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001;120:161‐9. - PubMed
Greco 1982
    1. Greco AV, Bianco A, Altomonte L, D'Acquarica L, Ghirlanda G. Effect of somatostatin on lower esophageal sphincter (LES) pressure and serum gastrin in normal and achalasic subjects. Hormone and Metabolic Research 1982;14:26‐8. [MEDLINE: ] - PubMed
Gøtzsche 1989
    1. Gøtzsche PC. Meta‐analysis of grip strength: most common, but superfluous variable in comparative NSAID trials. Danish Medical Bulletin 1989;36:493‐5. [MEDLINE: ] - PubMed
Hanisch 1992
    1. Hanisch E, Doertenbach J, Usadel KH. Somatostatin in acute bleeding oesophageal varices: pharmacology and rationale for use. Drugs 1992;44(Suppl 2):24‐35. [MEDLINE: ] - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ (Clinical Research Ed.) 2003;327:557‐60. - PMC - PubMed
Hopewell 2004
    1. Hopewell S, Clarke M, Stewart L, Tierney J. Time to publication for results of clinical trials (Cochrane Methodology Review). Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.MR000011.pub2] - DOI - PMC - PubMed
Kleber 1988
    1. Kleber G, Sauerbruch T, Fisher G, Paumgartner G. Somatostatin does not reduce oesophageal variceal pressure in liver cirrhotics. Gut 1988;29:153‐6. [MEDLINE: ] - PMC - PubMed
Lamberts 1996
    1. Lamberts SWJ, Lely A‐J, Herder WW, Hofland LJ. Octreotide. New England Journal of Medicine 1996;334:246‐54. [MEDLINE: ] - PubMed
McCormick 1992
    1. McCormick PA, Biagini MR, Dick R, Greenslade L, Chin J, Cardin F, et al. Octreotide inhibits the meal‐induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double‐blind, placebo‐controlled study. Hepatology 1992;16(5):1180‐6. [MEDLINE: ] - PubMed
Møller 1997
    1. Møller S, Brinch K, Henriksen JH, Becker U. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. Journal of Hepatology 1997;26(5):1026‐33. - PubMed
Nevens 1994
    1. Nevens F, Sprengers D, Fevery J. The effect of different doses of a bolus injection of somatostatin combined with a slow infusion on transmural oesophageal variceal pressure in patients with cirrhosis. Journal of Hepatology 1994;20(1):27‐31. [MEDLINE: ] - PubMed
Samnegaard 1980
    1. Samnegaard H, Tyden G, Thulin L, Friman L, Uden R. Effect of somatostatin on regional splanchnic blood flows in man: angiographic studies. Acta Chirurgica Scandinavica. Supplementum 1980;500:71‐3. - PubMed
Scherer 2004
    1. Scherer RW, Langenberg P. Full publication of results initially presented in abstracts (Cochrane Methodology Review). Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.MR000005.pub3] - DOI - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias, dimension of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408‐12. [MEDLINE: ] - PubMed
Sharara 2001
    1. Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. New England Journal of Medicine 2001;345:669‐81. - PubMed
Stern 1997
    1. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ (Clinical Research Ed.) 1997;315:640‐5. - PMC - PubMed
Williams 1994
    1. Williams SGJ, Westaby D. Management of variceal haemorrhage. BMJ (Clinical Research Ed.) 1994;308:1213‐7. [MEDLINE: ] - PMC - PubMed

References to other published versions of this review

Gøtzsche 1995
    1. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Somatostatin versus placebo in bleeding oesophageal varices: randomised trial and meta‐analysis. BMJ (Clinical Research Ed.) 1995;310:1495‐8. [MEDLINE: ] - PMC - PubMed
Gøtzsche 1997
    1. Gøtzsche PC. Somatostatin or octreotide versus placebo in bleeding oesophageal varices. The Cochrane Library 1997, Issue 3.
Gøtzsche 1998
    1. Gøtzsche PC. Somatostatin or octreotide versus placebo in bleeding oesophageal varices. The Cochrane Library 1998, Issue 1.
Gøtzsche 2002
    1. Gøtzsche PC. Somatostatin analogues for acute bleeding oesophageal varices (Cochrane Review). The Cochrane Library 2002, Issue 1. - PubMed
Gøtzsche 2005
    1. Gøtzsche PC, Hrobjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD000193.pub2] - DOI - PubMed

MeSH terms